The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma

Background and objective: Despite recent advances in treatment, glioblastoma (GBM) remains the most lethal and aggressive brain tumor. A continuous search for a reliable molecular marker establishes the methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter as a key prognostic factor in primary glioblastoma. The aim of our study was to screen Serbian patients with primary glioblastoma for an MGMT promoter hypermethylation and to evaluate its associations with overall survival (OS) and sensitivity to temozolomide (TMZ) treatment. Materials and methods: A cohort of 30 Serbian primary glioblastoma patients treated with radiation therapy and chemotherapy were analyzed for MGMT promoter methylation and correlated with clinical data. Results: MGMT methylation status was determined in 25 out of 30 primary glioblastomas by methylation-specific PCR (MSP). MGMT promoter hypermethylation was detected in 12 out of 25 patients (48%). The level of MGMT promoter methylation did not correlate with patients’ gender (p = 0.409), age (p = 0.536), and OS (p = 0.394). Treatment with TMZ significantly prolonged the median survival of a patient (from 5 to 15 months; p < 0.001). Conclusions: Due to a small cohort of primary GBM patients, our study is not sufficient for definitive conclusions regarding the prognostic value of MGMT methylation for the Serbian population. Our preliminary data suggest a lack of association between MGMT promoter methylation and overall survival and a significant correlation of TMZ treatment with overall survival. Further population-based studies are needed to assess the prognostic value of the MGMT promoter methylation status for patients with primary glioblastoma.

[1]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. , 2018, Neuro-oncology.

[2]  G. Fasola,et al.  Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme , 2018, Journal of Neuro-Oncology.

[3]  W. Poon,et al.  A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location. , 2018, World neurosurgery.

[4]  H. Ayatollahi,et al.  Prognostic Significance of MGMT Promoter Methylation in Patients with Glioblastoma Undergoing Surgical Intervention: A Retrospective Study in Northeastern Iran , 2018 .

[5]  T. Gupta,et al.  MGMT gene promoter methylation and its correlation with clinicopathological parameters in glioblastomas , 2018, Neurology India.

[6]  C. Wirtz,et al.  Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients? , 2018, Clinical Neurology and Neurosurgery.

[7]  A. Avan,et al.  The prognostic value of MGMT promoter methylation in glioblastoma: A meta‐analysis of clinical trials , 2018, Journal of cellular physiology.

[8]  A. Pais,et al.  Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches. , 2017, International journal of pharmaceutics.

[9]  W. Meng,et al.  Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis , 2017, Cancer management and research.

[10]  D. Grujičić,et al.  A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study. , 2017, World neurosurgery.

[11]  Massoud Saidijam,et al.  Detection of SPG20 gene promoter-methylated DNA, as a novel epigenetic biomarker, in plasma for colorectal cancer diagnosis using the MethyLight method. , 2017, Oncology letters.

[12]  Xianglin L. Du,et al.  Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study , 2017, Oncotarget.

[13]  Enshan Feng,et al.  Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis , 2017, European Neurology.

[14]  Jiye Li,et al.  IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy , 2016, Clinical Neurology and Neurosurgery.

[15]  C. Miracco,et al.  The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma , 2016, Clinical Neurology and Neurosurgery.

[16]  Sang Y Lee.  Temozolomide resistance in glioblastoma multiforme , 2016, Genes & diseases.

[17]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[18]  O. Visser,et al.  Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCARE-5 study. , 2015, European journal of cancer.

[19]  N. Rajeswari,et al.  Validation of Housekeeping Genes for Gene Expression Analysis in Glioblastoma Using Quantitative Real-Time Polymerase Chain Reaction , 2015, Brain tumor research and treatment.

[20]  H. Wheeler,et al.  Molecular Heterogeneity in Glioblastoma: Potential Clinical Implications , 2015, Front. Oncol..

[21]  T. Jiang,et al.  Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[22]  P. Goodfellow,et al.  Evaluation of incidence and prognostic significance of newly identified hotspot mutations in DNA polymerase epsilon (POLE) in endometrial cancer: Contextualizing findings from The Cancer Genome Atlas Research Network , 2014 .

[23]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[24]  P. Wen,et al.  The role of MGMT testing in clinical practice: a report of the association for molecular pathology. , 2013, The Journal of molecular diagnostics : JMD.

[25]  Lin Zhao,et al.  IDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta-Analysis , 2013, PloS one.

[26]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[27]  M. Weller,et al.  Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma , 2012, PloS one.

[28]  R. Lothe,et al.  MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR , 2012, Journal of Translational Medicine.

[29]  M. Copetti,et al.  High Specificity of Quantitative Methylation-Specific PCR Analysis for MGMT Promoter Hypermethylation Detection in Gliomas , 2009, Journal of biomedicine & biotechnology.

[30]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[31]  P. Liberski,et al.  High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations. , 2009, Cancer genetics and cytogenetics.

[32]  J. Behravan,et al.  Association Between MGMT Promoter Hypermethylation and p53 Mutation in Glioblastoma , 2009, Cancer investigation.

[33]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[34]  B. Scheithauer,et al.  The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.

[35]  P. Kleihues,et al.  Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.

[36]  K. Aldape,et al.  Molecular Features of Adult Glioma Associated with Patient Race/Ethnicity, Age, and a Polymorphism in O6-Methylguanine-DNA-Methyltransferase , 2005, Cancer Epidemiology Biomarkers & Prevention.

[37]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[38]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[39]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.

[40]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Kostic,et al.  Factors affecting the survival of patients with glioblastoma multiforme. , 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[42]  S. Artan,et al.  IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme. , 2015, Gene.

[43]  A. Dullea,et al.  MGMT testing allows for personalised therapy in the temozolomide era , 2015, Tumor Biology.